S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents

Fen Jiang(Vanderbilt University), Robert C. Briggs(Vanderbilt University), Vladimir Kravtsov(Vanderbilt University), Riet van der Meer(Vanderbilt University), Leanne A. Flye(Center for Innovation), David R. Head(University of Southern California), James O. Price(Vanderbilt University), Jingping Xie(Vanderbilt University), Keith Shults(Center for Innovation), Yuko Hashimoto(Vanderbilt University)

Leukemia Research

June 6, 2005

10.1016/j.leukres.2005.03.012

Cited by 13

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

|Blood|2000|1.6k

Age and acute myeloid leukemia

|Blood|2006|1.4k

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

|Blood|1997|869

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

|Journal of Clinical Oncology|1990|786

Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia

|New England Journal of Medicine|1991|722